Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
出版年份 2016 全文链接
标题
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
作者
关键词
-
出版物
Cell Death & Disease
Volume 7, Issue 1, Pages e2058
出版商
Springer Nature
发表日期
2016-01-18
DOI
10.1038/cddis.2015.275
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas
- (2017) M. N. Saleh et al. JOURNAL OF CLINICAL ONCOLOGY
- DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy
- (2015) Olga Grishina et al. BMC CANCER
- Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
- (2015) Madhusoodanan Mottamal et al. MOLECULES
- Chemoproteomics Reveals Time-Dependent Binding of Histone Deacetylase Inhibitors to Endogenous Repressor Complexes
- (2014) Isabelle Becher et al. ACS Chemical Biology
- Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins
- (2014) Min-Sung Lee et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors
- (2014) S Bauer et al. BRITISH JOURNAL OF CANCER
- Designer Proteins to Trigger Cell Death
- (2014) Wayne J. Fairbrother et al. CELL
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Regulation of hematopoietic and leukemic stem cells by the immune system
- (2014) C Riether et al. CELL DEATH AND DIFFERENTIATION
- A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
- (2014) J. E. Gray et al. CLINICAL CANCER RESEARCH
- Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
- (2014) Obinna Ubah et al. CURRENT PHARMACEUTICAL DESIGN
- Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines
- (2014) YongKu Ryu et al. EXPERIMENTAL BIOLOGY AND MEDICINE
- Apoptosis-inducing agents: a patent review (2010 – 2013)
- (2014) Ahmed Kamal et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Identification of predictive factors of response to the BH3-mimetic molecule ABT-737: Anex vivoexperiment in human serous ovarian carcinoma
- (2014) Stéphanie Lheureux et al. INTERNATIONAL JOURNAL OF CANCER
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
- (2014) Katrina J. Falkenberg et al. NATURE REVIEWS DRUG DISCOVERY
- High-Dose Cytarabine in Acute Myeloid Leukemia Treatment: A Systematic Review and Meta-Analysis
- (2014) Wei Li et al. PLoS One
- Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak
- (2014) L. M. Lindqvist et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Many players in BCL-2 family affairs
- (2014) Tudor Moldoveanu et al. TRENDS IN BIOCHEMICAL SCIENCES
- Systems biology of death receptor networks: live and let die
- (2014) I N Lavrik Cell Death & Disease
- Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?
- (2014) K Brinkmann et al. Cell Death & Disease
- Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation
- (2014) Richard L Momparler et al. Clinical Epigenetics
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma
- (2013) James R. Berenson et al. ANNALS OF HEMATOLOGY
- Targeting Apoptosis Pathways for New Cancer Therapeutics
- (2013) Longchuan Bai et al. Annual Review of Medicine
- Mathematical modeling of apoptosis
- (2013) Kolja Schleich et al. Cell Communication and Signaling
- The chains of death
- (2013) Kolja Schleich et al. CELL CYCLE
- Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
- (2013) H Inoue et al. CELL DEATH AND DIFFERENTIATION
- A Phase I Study of Quisinostat (JNJ-26481585), an Oral Hydroxamate Histone Deacetylase Inhibitor with Evidence of Target Modulation and Antitumor Activity, in Patients with Advanced Solid Tumors
- (2013) B. Venugopal et al. CLINICAL CANCER RESEARCH
- Cancer therapeutics: Targeting the apoptotic pathway
- (2013) Khurum H. Khan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials
- (2013) Tianzhu Qiu et al. Future Oncology
- Myc-driven endogenous cell competition in the early mammalian embryo
- (2013) Cristina Clavería et al. NATURE
- Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
- (2013) Peter E. Czabotar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
- (2013) Alexandra P. Zorzi et al. PEDIATRIC BLOOD & CANCER
- Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
- (2012) Mei Dong et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance
- (2012) D. Wroblewski et al. CARCINOGENESIS
- A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors
- (2012) U. Banerji et al. CLINICAL CANCER RESEARCH
- Phase I Trial of Vorinostat Combined With Bortezomib for the Treatment of Relapsing and/or Refractory Multiple Myeloma
- (2012) Donna M. Weber et al. Clinical Lymphoma Myeloma & Leukemia
- New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors
- (2012) Michele Cea et al. CURRENT PHARMACEUTICAL DESIGN
- Targeting the Bcl-2 family for cancer therapy
- (2012) Shibu Thomas et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
- (2012) Akira Fukutomi et al. INVESTIGATIONAL NEW DRUGS
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Trials with ‘epigenetic’ drugs: An update
- (2012) Angela Nebbioso et al. Molecular Oncology
- On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
- (2012) L Y Dimberg et al. ONCOGENE
- Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer
- (2011) G. Sonpavde et al. ANNALS OF ONCOLOGY
- Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours
- (2011) R Pili et al. BRITISH JOURNAL OF CANCER
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
- (2011) Andrew W. Roberts et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
- (2011) Paul K. Paik et al. LUNG CANCER
- A Unified Model of Mammalian BCL-2 Protein Family Interactions at the Mitochondria
- (2011) Fabien Llambi et al. MOLECULAR CELL
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Targeting apoptotic and autophagic pathways for cancer therapeutics
- (2010) Jun-jie Liu et al. CANCER LETTERS
- Smac Mimetic Increases Chemotherapy Response and Improves Survival in Mice with Pancreatic Cancer
- (2010) Sean P. Dineen et al. CANCER RESEARCH
- A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors
- (2010) R. S. Herbst et al. CLINICAL CANCER RESEARCH
- Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis
- (2010) Sameer A. Parikh et al. Clinical Lymphoma Myeloma & Leukemia
- Systems biology of apoptosis signaling networks
- (2010) Inna N Lavrik CURRENT OPINION IN BIOTECHNOLOGY
- IAP antagonists: promising candidates for cancer therapy
- (2010) Raimund Mannhold et al. DRUG DISCOVERY TODAY
- The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
- (2010) Paul A Marks EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Alternative cell death mechanisms in development and beyond
- (2010) J. Yuan et al. GENES & DEVELOPMENT
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
- (2009) Monica Galli et al. ANNALS OF HEMATOLOGY
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
- (2009) H. A. Wakelee et al. ANNALS OF ONCOLOGY
- The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy
- (2009) L. Ellis et al. BLOOD
- A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB
- (2009) Yao Dai et al. BMC CANCER
- An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer
- (2009) G. Liu et al. CLINICAL CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
- (2009) M. H. Kang et al. CLINICAL CANCER RESEARCH
- Phase I Study of YM155, a Novel Survivin Suppressant, in Patients with Advanced Solid Tumors
- (2009) T. Satoh et al. CLINICAL CANCER RESEARCH
- The role of BH3-only protein Bim extends beyond inhibiting Bcl-2–like prosurvival proteins
- (2009) Delphine Mérino et al. JOURNAL OF CELL BIOLOGY
- Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
- (2009) Richard L. Piekarz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Trial of AEG35156 Administered as a 7-Day and 3-Day Continuous Intravenous Infusion in Patients With Advanced Refractory Cancer
- (2009) Emma Dean et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
- (2009) Asher A. Chanan-Khan et al. LEUKEMIA & LYMPHOMA
- Understanding apoptosis by systems biology approaches
- (2009) Inna N. Lavrik et al. Molecular BioSystems
- Death receptor signal transducers: nodes of coordination in immune signaling networks
- (2009) Nicholas S Wilson et al. NATURE IMMUNOLOGY
- Cell Death
- (2009) Richard S. Hotchkiss et al. NEW ENGLAND JOURNAL OF MEDICINE
- BH3-only proteins and their roles in programmed cell death
- (2009) M Giam et al. ONCOGENE
- Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers
- (2008) C. Pepper et al. BLOOD
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
- (2008) S. M. O'Brien et al. BLOOD
- Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
- (2008) Barbara Pro et al. BRITISH JOURNAL OF HAEMATOLOGY
- Histone deacetylase inhibitors and genomic instability
- (2008) Grégory Eot-Houllier et al. CANCER LETTERS
- A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies
- (2008) S. J. Hotte et al. CLINICAL CANCER RESEARCH
- Molecularly Targeted Radiosensitization of Human Prostate Cancer by Modulating Inhibitor of Apoptosis
- (2008) Y. Dai et al. CLINICAL CANCER RESEARCH
- Survivin Antisense Oligonucleotides Effectively Radiosensitize Colorectal Cancer Cells in Both Tissue Culture and Murine Xenograft Models
- (2008) Franz Rödel et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Randomized Phase II Study of Carboplatin and Etoposide With or Without thebcl-2Antisense Oligonucleotide Oblimersen for Extensive-Stage Small-Cell Lung Cancer: CALGB 30103
- (2008) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin
- (2008) Anthony W. Tolcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
- (2008) F. Anthony Greco et al. LUNG CANCER
- BAX activation is initiated at a novel interaction site
- (2008) Evripidis Gavathiotis et al. NATURE
- IAP-targeted therapies for cancer
- (2008) E C LaCasse et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started